Treatment strategies to combat antimicrobial resistance in gastrointestinal infections

Abstract

The growing threat of antimicrobial resistance (AMR) necessitates the exploration of antibacterial therapeutic strategies to treat bacterial infections. This thesis explores metabolic targets for conventional and emerging therapies aimed at gastrointestinal (GI) infections caused by Escherichia coli (E. coli) and Clostridioides difficile (C. difficile). The research evaluates plant-based natural compound such as berberine, conventional antibiotics like azithromycin, and microbiome-based therapies including bacteriophages, bacteriophages combined with azithromycin, faecal microbiota transplantation (FMT) and faecal filtrates derived from FMT donors